Evidence map›Paper›PMID 40022152›Full record

ArticleMicrobiome2025

Roux-en-Y gastric bypass-associated fecal tyramine promotes colon cancer risk via increased DNA damage, cell proliferation, and inflammation.

Maria Glymenaki, Sophie Curio, Smeeta Shrestha, Qi Zhong, Laura Rushton, Rachael Barry, Mona El-Bahrawy, Julian R Marchesi, Yulan Wang, Nigel J Gooderham and 2 more

Abstract read
In one paragraph

Article in Microbiome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maria GlymenakiDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Sophie CurioDepartment of Life Sciences, Imperial College London, London, UK.
Smeeta ShresthaSingapore Phenome Center, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.
Qi ZhongDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Laura RushtonDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Rachael BarryDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Mona El-BahrawyDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Julian R MarchesiDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Yulan WangSingapore Phenome Center, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore.
Nigel J GooderhamDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Nadia GuerraDepartment of Life Sciences, Imperial College London, London, UK.
Jia V LiDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK. jia.li@imperial.ac.uk.

Funding

European Research Council (ERC) Starting Grant 715662Wellcome Trust
6 · The paper itself

Abstract

backgroundFecal abundances of Enterobacteriaceae and Enterococcaceae are elevated in patients following Roux-en-Y gastric bypass (RYGB) surgery. Concurrently, fecal concentrations of tyramine, derived from gut bacterial metabolism of tyrosine and/or food, increased post-RYGB. Furthermore, emerging evidence suggests that RYGB is associated with increased colorectal cancer (CRC) risk. However, the causal link between RYGB-associated microbial metabolites and CRC risk remains unclear. Hence, this study investigated the tyrosine metabolism of Enterobacteriaceae and Enterococcaceae strains isolated from patients post-RYGB and explored the causal effects of tyramine on the CRC risk and tumorigenesis using both human colonic cancer cell line (HCT 116) and wild-type and Apc

resultsWe isolated 31 bacterial isolates belonging to Enterobacteriaceae and Enterococcaceae families from the feces of patients with RYGB surgery. By culturing the isolates in tyrosine-supplemented medium, we found that Citrobacter produced phenol as a main product of tyrosine, whereas Enterobacter and Klebsiella produced 4-hydroxyphenylacetate, Escherichia produced 4-hydroxyphenyllactate and 4-hydroxyphenylpyruvate, and Enterococcus and two Klebsiella isolates produced tyramine. These observations suggested the gut bacterial contribution to increased fecal concentrations of tyramine post-RYGB. We subsequently evaluated the impact of tyramine on CRC risk and development. Tyramine induced necrosis and promoted cell proliferation and DNA damage of HCT 116 cells. Daily oral administration of tyramine for 49 days to wild-type mice resulted in visible adenomas in 5 out of 12 mice, accompanied by significantly enhanced DNA damage (γH2AX +) and an increased trend of cell proliferation (Ki67 +) in the ileum, along with an upregulated expression of the cell division cycle gene (Cdc34b) in the colon. To evaluate the impact of tyramine on intestinal tumor growth, we treated Apc

conclusionsOur results collectively suggested that RYGB-associated fecal bacteria could contribute to tyramine production and tyramine increased CRC risk by increasing DNA damage, cell proliferation, and pro-inflammatory responses of the gut. Monitoring and modulating tyramine concentrations in high-risk individuals could aid CRC prognosis and management. Video Abstract.

Indexed as

Colonic NeoplasmsDNA DamageFecesGastric BypassTyramineAnimalsCell ProliferationEnterobacteriaceaeFemaleGastrointestinal MicrobiomeHCT116 CellsHumansInflammationMaleMiceMice, Inbred C57BLTyramineBariatric surgeryColon cancer riskHost-microbial interactionInflammatory bowel disease (IBD)Prevention

Identifiers

PMID40022152
PMCPMC11869571

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.